

Abstract deadline: 15 November 2023 - 21.00 pm (CET)

Abstract Policy and Regulations

With the submission of an abstract to 14th European Breast Cancer Conference (EBCC-14), the presenting author:

- Certifies to be an investigator with substantial involvement in the clinical study presented in the abstract.
- Accepts responsibility for the accuracy of the submitted abstract.
- Accepts to be the contact person for all correspondence regarding the abstract and inform co-authors of its status.
- Confirms that all co-authors are aware of and agree to the content of the abstract and support the data presented.
- Warrants that the data and conclusions presented in the abstract have not been presented or published at any meeting of 500 delegates or more prior to the EBCC-14 conference.
- Agrees to submit updated data for important large studies presented (in part) at previous meetings. Violation of this policy may result in rejection of the submitted abstract.
- Certifies that the information in the abstract is for exclusive presentation in the European Breast Cancer Conference Scientific Programme and will not be presented during the EBCC-14 at any Satellite Symposia.
- States that for all studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and informed consent given where appropriate.
- For abstracts containing clinical trial data include: Trial abbreviation; Trial Registry Number or ID background; Objective, Design, Population studied (including sample size), Intervention, Outcome measure (s), Analysis, Trial status, Trial sponsor(s)
- Identifies, obtains and discloses any financial interest in products or processes described in the abstract for all abstract authors. This includes stock ownership, membership on an advisory board or board of directors, corporate-sponsored research and other substantive relationships.
- The copyright of the abstract(s) are retained by the author(s). However, the author(s) give permission to the EBC Council to print the abstract(s) in the EJC as well as on the EBCC-14 website.
- Trials in Progress abstracts will not be accepted.
- Abstracts on case studies will be rejected.

Abstract Preparation and Submission

- Abstracts must be submitted in **good English and carefully proofread** to ensure the accuracy of published material. The Scientific Committee reserves the right to reject abstracts submitted in poor English, or may request an immediate revision by the author.
- Authors may provide their preference of presentation format: oral, poster or no preference.
- Please choose one main **topic** to categorise.
The Scientific Committee has the authority to re-categorise the abstract.
- The **title of the abstract** should be concise and accurately describe the study undertaken. Do not use non-standard abbreviations and commercial names (generic names only).
- Abstracts should be structured to include the following **4 sections**:
Background: introductory sentence specifying the purpose of the study
Material and methods: brief description of relevant experimental procedures
Results: summary of the results of the investigation
Conclusions: a statement of the main conclusions
- The abstract submission system will not accept abstracts that **exceed 2900 characters (including body of the abstract, spaces and one table)**.
- **Only one data** table is permitted in the body of the abstract. Illustrations and figures are not allowed and will be deleted if submitted.
- **Abbreviations** may be used if standard or if spelled out and defined at the first use (put in parentheses immediately after the first mention of a term or phrase). Compounds should be mentioned with the generic name, in lower cases. Commercial names are admitted in the text, with an ®, and if in brackets following the generic name, i.e. “generic (Commercial ®)”.
- Up to 3 **keywords** should be provided to distinguish the abstract for indexing purposes.
- **No more than 20 authors** can be listed with only their institutional affiliation(s), city and country. Mailing addresses and academic degrees should not be mentioned. For co-operative study groups, the name of the group should be used instead of individual institutional affiliations or include the name of the group in the title of the abstract.
- An e-mail confirming **receipt of the abstract** submitted online will be sent to the presenting author within 48 hours. An **abstract number** will be allocated and should be mentioned for any queries relating to the submitted abstract.



Awards

European Breast Cancer Council Multidisciplinary TEam Award (EBCC MTEA)

What is it? A new prestigious award for a multidisciplinary team conducting impactful research related to breast cancer.

Why EBCC MTEA? The European Breast Cancer Conference prides itself on offering state-of-the-art education, but this year we also want to provide a forum for original research to be presented.

EBCC-14 aims to attract high quality original multidisciplinary research in breast cancer. The main topic of EBCC-14 will be research and innovation in the multidisciplinary management of breast cancer. For this reason, we are launching the prestigious EBCC MTEA.

Who is eligible? Multidisciplinary teams that submit an original research abstract to EBCC-14 in the fields of medical oncology, surgical oncology, radiotherapy, medical imaging, survivorship, translational and basic research, and health care research related to breast cancer not previously published or presented in another conference. The work needs to be multidisciplinary.

What EBCC MTEA provides? The multidisciplinary team award recipients will receive 5 000 EUR, free travel arrangements, accommodation, registration to the conference and an invitation to the faculty dinner for 3 people.

To apply, you will first need to [submit an abstract](#). Please note on submission that you wish to be considered for this award.

*Deadline for Abstract Submission is **15 November 2023**.*

What is the EBCC MTEA selection procedure?

The **EBCC scientific committee** that has reviewed all the abstracts submitted to EBCC will provide to the **EBCC MTEA selection committee** a list of the top submitted abstracts that involve multidisciplinary work. The **EBCC MTEA selection committee** will further select among the top abstracts based on the criteria of excellence, innovation and impact for the patient and the society. Then, the committee will invite the multidisciplinary team of the selected abstract to submit a 2-page outline of the importance of the present work and the next steps the team plans to take. Only one multidisciplinary team will be selected to receive this award.



European Breast Cancer Council Young Investigator Innovation Award (EBCC YIIA)

What is it? A new prestigious award in medical oncology, surgical oncology, radiotherapy, medical imaging, survivorship, translational and basic research, and healthcare research related to breast cancer.

Why EBCC YIIA? On top of providing a state-of-the-art educational programme, EBCC-14 aims to attract high-quality original research in the areas of medical oncology, surgical oncology, radiotherapy, medical imaging, survivorship, translational and basic research, and health care research related to breast cancer. The main topic of the conference is 'research and innovation in the multidisciplinary management of breast cancer'.

Who is eligible? Early and mid-career investigators up to **45 years of age** that submit an original research abstract to EBCC-14 in the fields of medical oncology, surgical oncology, radiotherapy, medical imaging, survivorship, translational and basic research, and health care research related to breast cancer not previously published or presented in another conference.

What EBCC YIIA provides?

The winner of the EBCC YIIA award will receive 5 000 EUR, free travel arrangements, accommodation, registration to the conference and an invitation to the faculty dinner.

To apply, you will first need to [submit an abstract](#). Please note on submission that you wish to be considered for this award.

*Deadline for Abstract Submission is **15 November 2023**.*

What is the EBCC YIIA selection procedure?

The **EBCC scientific committee** that has reviewed all the abstracts submitted to EBCC will provide to the **EBCC YIIA selection committee** a list of the top submitted abstracts. The **EBCC YIIA selection committee** will further select among the top abstracts based on the criteria of excellence, innovation and impact for the patient and the society. Then, the committee will invite the author of the selected abstract to submit a 5-page CV and a 2-page outline of the importance of the present work and the next steps she/he plans to take. Only one candidate will be selected to receive this award.



Abstract Selection Process

Abstracts submitted for presentation in the EBCC-14 will be reviewed by an international panel of experts in the field of the subject and will be judged solely on the data submitted. The final decision on the presentation format of all selected abstracts lies at the sole discretion of the Scientific Committee.

Possible presentation formats are applicable at the EBCC-14:

Oral presentation

Abstracts of superior quality can be selected for presentation in a session where discussants will place the research findings into perspective.

Poster Presentation

Abstracts that have been selected for poster presentation will be displayed on poster boards in a prominent poster viewing area. The posters will be grouped by topic and displayed for one day. A specific time will be devoted to poster viewing to ensure delegates have sufficient opportunity to acquaint themselves with the presented data.

Poster Spotlight Sessions

The Scientific Committee will make a special selection of posters which will be highlighted through short oral presentations followed by moderated discussion. These sessions will facilitate dynamic exchange on selected findings of broad interest.

Registration

Submitting an abstract for presentation in the EBCC-14 does not constitute registration for the conference. When selected, abstract presenters must register to attend the European Breast Cancer Conference in Milan.

The presenting author will receive a letter with the result of the review and the Scientific Committee's decision on the abstract by **end of January 2024**.

Abstract Withdrawal

EORTC cannot guarantee any request for withdrawal of an abstract that in any way delays the publications. Requests to withdraw abstracts will be **accepted until 15 February 2024**.

After this date, abstracts selected for presentation must be presented. If the presenting author of a selected abstract cannot attend, they should assign a replacement and inform EBCC secretariat of the replacement as soon as possible.

The logo for the European Breast Cancer Conference (EBCC) features the letters 'EBCC' in a large, bold, white font against a blue background.

EUROPEAN
BREAST CANCER
CONFERENCE

14

14TH EUROPEAN BREAST
CANCER CONFERENCE

Research & Innovation in the Multidisciplinary Management of Breast Cancer
20-22 March 2024 | Milan, Italy



Embargo Policy

The European Breast Cancer Conference intends to publish selected abstracts online on its website 2 weeks before the conference. You must inform us by e-mail if you do not want your abstract published online 2 weeks before the conference (this will also be mentioned in the abstract acceptance/rejected mail). If we do not receive a response to this e-mail, your abstract will be automatically published online.

Abstracts, where the author does not consent, will be published on the first day of the conference except for Oral, Late Breaking and Media selected abstracts which will be published on the day of the presentation.

Information contained in the abstract as well as additional data and information to be presented must not be made public before the abstract has been presented at the EBCC-14 conference.

The first author and co-authors must not release the research/study to news media. If the policy is violated, the abstract will be automatically withdrawn from presentation and from publication online.